BRAF inhibitors are widely used to treat melanoma with BRAF-V600 mutations, and encorafenib is also approved, in combination with cetuximab, for metastatic CRC with BRAF-V600E mutation, which is the predominant BRAF mutation in CRC [29]. The gene discussed is BRAF; the disease is colorectal carcinoma.